TherapeuticsMD (TXMD) Misses Q1 EPS by $1.69
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
TherapeuticsMD Announces First Quarter 2022 Financial Results
May 16, 2022 4:05 PM EDT
- Quarterly total net product revenue of $19.3 million -
- ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 -
- Announced and completed vitaCare divestiture in five weeks -
- Conference call scheduled for 4:30 p.m. ET today -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (TXMD or the Company) (NASDAQ: TXMD), an innovative, leading womens healthcare company, today reported financial results for the first quarter ended March 31, 2022.
Our revenue performance during the quarter was impacted by ANNOVERA manufacturing challenges as anticipated, but we believe these... More
